Group Medical Visits for Patients With Dyslipidemia
Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve c
| Condition(s) | Dyslipidemias |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of |
| Who can participate | Inclusion Criteria: * Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol/L or non-HDL-C ≥ 4.2 mmol/L or ApoB ≥ 1.05 g/L Exclusion Criteria: * Patients unable to participate in GMV sessions or to provide informed consent * Patients with a mental health condition likely to limit their ability to benefit from GMV sessions and discussions (Examples: severe dementia or an acute psychiatric decompensation occurring within the past six months) * A diagnosis of terminal illness or a life expectancy of less than 12 months |
| Ages | 40 Years |
| Sex | All |
| Lead sponsor | Université de Sherbrooke |
| Locations | Dieppe, New Brunswick, Canada |
| Start date | 2026-04 |
| NCT ID | NCT07543718 |
| Official listing | https://clinicaltrials.gov/study/NCT07543718 |